| J9271 | Injection, pembrolizumab, 1 mg | 21,000 | $40 | $903K |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase‑fihj | 9,900 | $40 | $376.2K |
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 760 | $160 | $120.2K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 540 | $140 | $75.2K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 650 | $110 | $71K |
| J0897 | Injection, denosumab, 1 mg | 3,720 | $20 | $70.7K |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 730 | $70 | $52.7K |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | 7,900 | $10 | $47.4K |
| 99205 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider… | 120 | $200 | $22.8K |
| 99233 | The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a high level of medical decision making or the… | 200 | $110 | $21.7K |